42 results
8-K
EX-3.2
LABP
Landos Biopharma Inc
23 May 24
AbbVie Completes Acquisition of Landos Biopharma
4:29pm
, without limitation, court costs, attorneys’ fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature
DEFM14A
LABP
Landos Biopharma Inc
25 Apr 24
Proxy related to merger
5:07pm
in nature and, therefore, should be read in light of the factors discussed under “Forward-Looking Statements.”
Certain Financial Projections
Landos does … multiple years, by their nature, they become subject to greater uncertainty with each successive year and are unlikely to anticipate each and every
PREM14A
LABP
Landos Biopharma Inc
15 Apr 24
Preliminary proxy related to merger
5:18pm
information presented in this section is forward-looking in nature and, therefore, should be read in light of the factors discussed under “Forward … that are inherently uncertain. Because the Projections cover multiple years, by their nature, they become subject to greater uncertainty with each
DEFA14A
LABP
Landos Biopharma Inc
25 Mar 24
Additional proxy soliciting materials
9:19am
Section 3.2
Certificate of Incorporation and Bylaws
Section 3.3
Capitalization
Section 3.4
Authority; Binding Nature of Agreement
Section 3.5
Non …
Section 4.3
Authority; Binding Nature of Agreement
Section 4.4
Non-Contravention; Consents
Section 4.5
Information Supplied
Section 4.6
Absence
8-K
EX-2.1
qeghta0x9y he
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
8:54am
8-K
EX-10.1
esah m90w
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
8:54am
PRE 14A
rs8w53z4
10 Apr 23
Preliminary proxy
4:20pm
DEF 14A
0huy s6xfsl6fl
28 Apr 22
Definitive proxy
4:16pm
S-3
j4yxsjo v0aehrfjj8b
24 Mar 22
Shelf registration
5:26pm
S-3
EX-4.2
ibph7lovl9cfr ksyli
24 Mar 22
Shelf registration
5:26pm